precisioms (CV) of 5.7% and 8.7% at 100 and 500 1g/L, respectively (n = 12). Between-run precisions (CV) are 4.2% and 5.4% at 100 and 500 gfL, respectively (n = 5). The assay is specific for the parent drug cyclosporine, and results correlate well with those by HPLC (r = 0.98, slope = 0.95, n = 23). Stability of the assay is excellent; results changed by <5% in three months, suggesting that no recalibration was needed over this period.
F.R.G.)
Antibodies to nuclear antigens (ANA, antinuclear antibodies), a hallmark of systemic rheumatic diseases, have become important aids in the diagnosis of connective-tissue diseases and one of the most abundant tests in the rheumatological laboratories (1, 2). More than 50 different nuclear antigens and their corresponding antibodies have been identified in patients with autoimmune diseases, the most important of which are antibodies to double-and single-stranded DNA, histones, topoisomerase I (anti-Sd-70), and nuclear ribonucleoproteins (anti-Sm,1 anti-RNP,
anti-SS-A,
anti-SS-B). Anti-Sm and anti-RNP antibodies react with proteins of small nuclear ribonucleoprotein particles (sn-RNP). These particles, which seem to be involved in nuclear functions, e.g., splicing of RNA (3), are composed of uridine-rich RNAs of low molecular mass and a set of at least 11 polypeptides, ranging from about 10 to 70 kDa (70-kDa protein, and proteins A, A', B, B', B", C, D, E, F, G) (4) (5) (6) . As has been shown by Western blot techniques, antibodies to the 70-kDa protein (sera with anti-RNP reactivity) represent a dominant marker of mixed connective-tissue disease (MCTD) (7) , whereas antibodies to the D protein (sera with anti-Sm reactivity) may prevail in systemic lupus erythematosus (SLE) (4, 7). Sera with anti-RNP or anti-Sm activity also may contain antibodies to some of the others of the above-mentioned polypeptides (7, 8). The diagnostic value of these latter antibodies remains to be established.
Because no specific tests except Western blot techniques are available to differentiate the various anti-sn-RNP antibody speciflcities, we wanted to establish ETA tests to detect antibodies against the various sn-RNP-peptides.
Therefore, in a first attempt we isolated and sequenced c-DNAs of the major marker antigens of U-sn-RNP (70-kDa protein, B/B' and D) peptides, expressed the proteins in Escherichia coli, and synthesized peptide epitopes according to the sequence data.
Antibodies to 70-kDa protein: An insert of 1293 bp of the c-DNA encoding 87% of the 70-kDa protein (9) was subcloned into pEMBL vector and ligated into the expression vector pEX34b (10), which was transferred into E. coli strain 537 containing a temperature-sensitive mutant of the lambda repressor ci on a kanamycin-resistant plasmid (pcI 857) (11). The fusion protein was purified by diethylaminoethyl column chromatography (linear gradient of NaCl, 5 mol/L urea, 10 mmol/L Tris-HC1, pH 7.4). Fractions that were eluted with NaCl between 350 and 550 mmol/L contained essentially pure 70-kDa fusion protein components as judged by SDS-PAGE and immunoblotting
(12).
For antibody screening in patients' sera, we developed a sandwich EIA, using polystyrene microtiter plates coated with the purified fusion protein (0.7 L.g/mL in carbonate buffer, pH 9.5). For estimation of anti-RNP or anti-Sm activity, adjacent wells were coated with a fraction of calf thymus nuclear extract (20 p.g/mL in carbonate buffer, pH 9.5), the fraction that was precipitated with 30-60% saturated ammonium sulfate. This was used both as native material (CTE) and as RNase-treated extract (CTERNase). [RNase destroys the RNP antigenicity, leaving the Sm-antigen intact (13, 14) .] Antibody screening was performed with peroxidase-labeled anti-human IgG, by standard techniques (15) . None of the 654 control sera (sara submitted for ANA screening), which were negative with CTE and CTE-RNase, showed antibodies reacting with the 70-kDa protein (Table 1) . Another 76 sara gave positive results with CTE-RNase and CTE but did not react with the 70-kDa protein. About half of these 76 sera revealed antibodies reacting with Sm-antigen (B/B' and D) or with A and C polypeptides of RNP, as shown by Western blotting; the remaining sera reacted with several unidentified proteins not belonging to the U-sn-RNP group. Thirty-three sera reacted with all the three antigens; as confirmed by Western blotting, they also could be classified to contain anti-Sm (anti-D protein) and anti-RNP (anti-70-kDa protein) reactivity.
Thirty-six sera reacted only with nondigested CTE and the 70-kDa protein (anti-RNP reactivity). sara as well as with eight negative control sera, use of this synthetic peptide as antigen for antibody screening would be superior to the fusion protein, owing to the higher purity of the synthetic peptide.
Antibodies to D protein: The amino acid sequences of the N-terminal and other tryptic peptides were kindly provided by R. L#{252}hrmann. Using the same library as in the isolation of the B/B' clones, we screened with a 29mer mixture of oligonucleotides constructed according to the amino acid sequence of the N-terminal peptide. The 555-bp-long EcoRI insert of one clone was completely sequenced (Figure 1,  bottom) . An open reading frame of 357 bp encoded a protein of 119 amino acids having a calculated molecular mass of 13.3 kDa, which is in the range of that estimated by SDS-PAGE.
The coding region of this clone is identical to that of a Sm-D clone, published while this work was in progress (17) A T P P P G I H A P P P C H P P P H C P P I C 
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